|
WO2021081446A1
|
|
Systems and methods for electronic portfolio management
|
|
WO2021081280A1
|
|
Adeno-associated virus vectors based gene therapy for hereditary angioedema
|
|
WO2021055621A1
|
|
Plasma kallikrein inhibitors and uses thereof
|
|
US2021079022A1
|
|
Heteroaryl plasma kallikrein inhibitors
|
|
WO2021021615A1
|
|
Recombinant heme oxygenase-1 (ho-1) for the treatment of sickle cell disease
|
|
WO2020252136A1
|
|
Adeno associated viral vector delivery of antibodies for the treatment of disease mediated dysregulated plasma kallikrein
|
|
WO2020219874A1
|
|
Isofagomine salts, methods of use and formulations
|
|
WO2020132452A1
|
|
Purification of iduronate-2-sulfatase immunoglobulin fusion protein
|
|
WO2019246521A1
|
|
Anti-flt-1 antibodies in treating bronchopulmonary dysplasia
|
|
KR20200143376A
|
|
Substituted imidazopyridines and uses thereof as plasma kallikrein inhibitors
|
|
EP3762399A1
|
|
Affinity purification of glycoside-cleaving enzymes
|
|
US2019250070A1
|
|
Syringe screening device
|
|
WO2019136224A1
|
|
Amphetamine-guanfacine combinations for treatment of neuropsychiatric disorders
|
|
US2020384089A1
|
|
Purified arylsulfatase a and compositons thereof
|
|
CN111542296A
|
|
Device and method for detecting dose delivery
|
|
BR112020007820A2
|
|
formulations comprising glucocerebrosidase and isofagomine
|
|
WO2019051474A1
|
|
Methods and compositions for treating chronic lung diseases
|
|
WO2019027876A1
|
|
Antibody-resin coupling apparatus and methods
|
|
EP3621986A1
|
|
Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy
|
|
WO2018144742A1
|
|
Compounds and compositions for the treatment of ophthalmic disorders
|
